

COMPARATIVE EFFECTIVENESS OF TOFACITINIB VERSUS UPADACITINIB FOR THE TREATMENT OF ACUTE SEVERE ULCERATIVE COLITIS: RESULTS OF AN INTERNATIONAL MULTICENTER STUDY

Matthieu Uzzan

UEG Week Berlin 2025

Poster

IBD

October 5, 2025

This multicenter retrospective study of 111 hospitalized patients with acute severe ulcerative colitis found that tofacitinib and upadacitinib had similar effectiveness for inducing remission and preventing colectomy with comparable safety profiles.

KEY POINTS

- Upadacitinib showed higher early response rates at days 3-7 (84% vs 54%, $p=0.02$), but clinical response and remission rates were comparable between the two JAK inhibitors at day 98 and day 182.
- Colectomy-free survival probabilities at days 98 and 182 were similar for tofacitinib (79%/75%) and upadacitinib (80%/78%) with no significant difference ($p=0.99$).
- In sub-analysis of salvage therapy use (tofacitinib $n=35$, upadacitinib $n=31$), effectiveness outcomes were similar across both groups.
- Adverse event frequencies were comparable between the two treatments across the 111 patients enrolled from 23 international centers.
- This is the first comparative study and largest case series of JAK inhibitors in acute severe ulcerative colitis, though the authors note that prospective studies with longer follow-up are needed to validate findings.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/fa40437a-a812-11f0-8d18-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.